The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...

Stocks declined on Thursday as rising tensions in the Middle East left investors uneasy ahead of September's payrolls report.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.